|Targets||Ribosomal S6 Kinase (RSK)|
|Description||LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.|
|Related CAS||1082949-67-4 (Free base)|
|Appearance||White to off-white solid powder|
|Synonyms||4-(4-(4-(4-fluoro-3-(trifluoromethyl)phenyl)-1-methyl-1H-imidazol-2-yl)piperidin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine 4-methylbenzenesulfonate; LY2584702; LY 2584702; LY-2584702; LYS6K2|
FMK is a potent, highly specific and irreversible ribosomal s6 kinase (RSK) inhibitor that covalently modifies the C-terminal kinase domain of RSK. Its IC50 val...
LJI308 is a RSK inhibitor. LJI308 overcomes chemoresistance by eliminating cancer stem cells. LJI308 targets the CSC population and repress TNBC growth and diss...
The hydrochloride salt form of LY2584702 which is a selective ATP competitive inhibitor of p70 S6 kinase. LY2584702 is still under Phase I trial for evaluating ...
BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM, respectively; 10- to 100-fold selectivity for RSK t...
BIX 02565, a RSK2 inhibitor, has also been found to significanltly influence sorts of adrenergic receptor subtypes involved in ascular tone and cardiac function...
CMK is a RSK2 kinase inhibitor. Its IC50 value for Cdc5(L158G) is 36 nM. It is used in the preparation of serine/threonine kinase inhibitors.
Pluripotin, also known as SC-1, is a potent and selective activator of murine embryonic stem (ES) cell self-renewal. Pluripotin works through dual inhibition of...
DG2 is a potent and selective inhibitor of p70 ribosomal S6 kinase 1 (S6K1) (IC50 = 9.1 nM) with ATP-competitive and cell-permeable properties.
LY2584702 is an orally available inhibitor of p70S6K signaling, with potential antineoplastic activity.
LJH685, binding to the RSK2 N-terminal kinase ATP-binding site, is a potent inhibitor that specificlly targets RSK with antiproliferative effects in MAPK pathwa...
LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
PF-4708671 is a novel cell-permeable inhibitor of S6K1. PF-4708671 specifically inhibits the S6K1 isoform with a Ki of 20 nM and IC50 of 160 nM. PF-4708671 pre...